Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.

Minerva medica - 1 Oct 2020

Cafaro Alessandro, Giannini Maria B, Silimbani Paolo, Cangini Delia, Masini Carla, Ghelli Luserna Di Rorà Andrea, Simonetti Giorgia, Martinelli Giovanni, Cerchione Claudio

Abstract excerpt

Over the last few years, we assisted to an increasing knowledge about acute myeloid leukemia (AML) pathobiology. However, outcomes remain unsatisfactory particularly for adult patients over 60 years old. Not surprisingly several cases of therapy-related AML (tAML) and secondary AML, both characterized by poorer prognosis, are more common in older population. For several decades initial therapy for AML remained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cytarabine

Share to Daunorubicin

Share to Leukemia, Myeloid, Acute

Share to Liposomes

Share to Myelodysplastic Syndromes

Source

Identifiers

PMID: 32955826
DOI: 10.23736/S0026-4806.20.07017-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.PMID 32955826Read ↗

The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and SafetySemantic proximity Read ↗

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.Semantic proximity Read ↗

The most novel of the novel agents for acute myeloid leukemia.Semantic proximity Read ↗

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.Semantic proximity Read ↗

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.Semantic proximity Read ↗

[AML in Adults - An Update on Diagnosis, Risk Classification and Therapy].Semantic proximity Read ↗

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patientsSemantic proximity Read ↗

Novel therapeutic strategies for AML in 2012.Semantic proximity Read ↗

The new era of AML therapy: current standards and emerging targets.Semantic proximity Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.Semantic proximity Read ↗

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.